45.1$

44.4$

0.71.6%$

192.7$

168.7$

24.014.2%Kuvan (2) 27.322.74.620.3%99.476.822.629.4%Firdapse (3) 3.00.03.0N/A6.40.06.4N/A(1) Changes in foreign currency rates, net of hedges, had a negative $0.1 million impact on Naglazyme sales in the three months ended December 31, 2010 and a negative $1.7 million impact on Naglazyme sales for the year ended December 31, 2010.  Naglazyme revenues experience quarterly fluctuations due to the timing of government ordering patterns in certain countries.

(2) The quantity of commercial tablets dispensed to patients in the U.S. increased 5.0 percent in the fourth quarter of 2010 compared to the third quarter of 2010 and increased 16.4 percent in the fourth quarter of 2010 compared to the fourth quarter of 2009.

(3) A product for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS) which was launched in the EU in April 2010. Three Months Ended December 31, Years Ended December 31,20102009$ Change% Change 20102009$ Change% Change Aldurazyme revenue reported by Genzyme (4) $

42.5 $

38.7 $

 3.8 9.8%$

166.8 $

155.1 $

11.7 7.5%Royalties due from Genzyme 17.8 15.7  2.1   68.0   61.8   6.2 Incremental (previously recognized) Aldurazyme
product
transfer
revenue   5.3   1.1  4.2 3.2 8.4  (5.2)Total Aldurazyme net product revenues (5)$

23.1 $

16.8 $

 6.3 $

  71.2 $

  70.2 $